FIELD: pharmaceutics.
SUBSTANCE: invention relates to a compound of formula I or its pharmaceutically acceptable salts thereof. Compound of formula (I) possess the properties of BACE1 and/or BACE2. In formula I:
R1 represents a 6-member heteroaryl containing 2 heteroatoms selected from N substituted with a substitute C2-6-alkynyl-C-1-6-alkoxy; R2 is a halogen atom; R3 is C1-6-alkyl; R4 is selected from a halogen atom; R5 is selected from a halogen atom; R6 is selected from a hydrogen atom, and R7 is selected from a hydrogen atom. Invention also relates to a tritium labelled compound of formula Ia, 11C-labelled compound of formula Ia', structural formulae are given in the claim, to a method for diagnostic imaging BACE1 enzyme, use of compounds when preparing the composition for diagnostic imaging BACE1, to a pharmaceutical composition, use of compounds in preparing a drug, to a method of inhibiting activity BACE1 and/or BACE2.
EFFECT: obtaining novel compounds of formula I possessing the properties of BACE1 and/or BACE2.
33 cl, 7 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
2-AMINO-5,5-DIFLUORO-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND(OR) BACE2 INHIBITORS | 2010 |
|
RU2515221C2 |
N-[3-(5-AMINO-3,3A,7,7A-TETRAHYDRO-1H-2,4-DIOXA-6-AZA-INDEN-7-YL)-PHENYL]-AMIDES AS INHIBITORS OF BACE1 AND(OR) BACE2 | 2012 |
|
RU2597308C2 |
2, 5, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-3-YLAMINES OR 2, 3, 6, 7-TETRAHYDRO-[1, 4]OXAZEPIN-5-YLAMINES | 2011 |
|
RU2570796C2 |
CONDENSED TRIAZOLAMINES AS P2X7 MODULATORS | 2010 |
|
RU2533122C2 |
CAMPTOTHECIN ANALOGS, METHODS OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1997 |
|
RU2190613C2 |
BETA-SECRETASE INHIBITORS | 2016 |
|
RU2712272C2 |
NEW BICYCLIC COMPOUNDS OF THIOPHENYLAMIDE | 2013 |
|
RU2644565C2 |
BICYCLIC NITROIMIDAZOLES COVALENTLY CONNECTED TO REPLACED PHENYLOXAZOLYDINONES | 2009 |
|
RU2504547C2 |
PYRAZOLAMINOPIRIMIDINE DERIVATIVES AS LEUCINE-REPEATING KINASE 2 (LRRK2) MODULATORS FOR TREATMENT OF PARKINSON DISEASE | 2013 |
|
RU2637948C2 |
COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
Authors
Dates
2016-10-10—Published
2012-06-04—Filed